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ABSTRAK
Tujuan: mengevaluasi dosis efektif dan efek samping pemberian BCG. Metode: dilakukan pencarian 
publikasi uji klinis acak di Medline dan Cochrane sebelum Oktober 2013. Penelitian yang berkaitan dengan 
pemberian BCG setelah TUR dan pemantauannya pada pasien kanker kandung kemih non-otot invasif (KKKNIO) 
dengan risiko sedang dan tinggi dimasukkan sebagai kriteria inklusi. Kriteria eksklusi meliputi pasien KKKNIO 
risiko rendah, pemberian BCG dengan dosis lain dan kanker buli infasif otot. Hasil: studi meta-analisis 6 uji klinis 
yang meliputi 2719 pasien KKKNIO risiko sedang-tinggi menunjukkan angka kekambuhan setelah pemberian 
dosis penuh (81 mg), dosis rendah (27 mg) dan dosis sangat rendah (13,5 mg) berturut-turut 33,3%, 34,7%, 
dan 30%. Meta analisis (2175 pasien), dosis BCG 81 mg menghasilkan hasil yang lebih baik dari dosis 27 
mg dalam mengurangi kekambuhan tumor (RR 0,86; 95% CI 0,77-0,96, I2 = 0% dan p=0,008). Meta-analisis 
(544 pasien), efektivitas dosis rendah dinilai lebih tinggi dibandingkan dengan dosis sangat rendah (RR 0,66; 
95% CI 0,49-0,89, I2 = 8,8% dan p=0,006). Efek samping sistemik terjadi pada 25% dosis tinggi, 28,5% dosis 
rendah, dan 15,5% dosis sangat rendah. Dosis rendah dinilai superior terhadap dosis penuh pada efek samping 
sistemik (p=0,000) namun tidak terhadap efek samping lokal (p=0,137) pada 2 meta analisis (1816 pasien). 
Kesimpulan: dosis penuh BCG memiliki hasil superior dalam hal menurunkan angka kekambuhan KKKNIO 
dibandingkan dengan dosis rendah atau sangat rendah. Tidak ada perbedaan bermakna antara dosis terhadap 
efek samping lokal. Namun, dosis penuh memiliki angka efek samping sistemik yang lebih tinggi dibandingkan 
dengan dosis rendah dan sangat rendah.
Kata kunci: Bacillus Calmette-Gue´Rin, dosis dan efek samping, kanker kandung kemih non-otot invasif 
(KKKNIO).
ABSTRACT
Aim: to evaluate the effective dose and adverse effects of BCG doses. Methods: we searched published 
RCTs in Medline and Cochrane database before October 2013. Article using maintenance BCG after TUR 
in intermediate-high risk non-muscle invasive bladder cancer (NMIBC) and followed for effectiveness, local 
and systemic side effect are included. Low risk patients, other dose and MIBC were excluded. Results: meta-
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analysis of 6 clinical trials involving 2719 intermediate-high risk NMIBC patients showed recurrence rate in 
full dose (81 mg), low dose (27 mg) and very low dose (13.5 mg) were 33.3%, 34.7% and 30%, respectively. 
Meta-analysis of 2175 patients, 81 mg BCG was found to be superior to 27 mg in reducing tumour recurrences 
(RR 0.86; 95% CI 0.77-0.96, I2 = 0% and p=0.008).  Meta-analysis of 544 patients, the effectiveness reducing 
tumour recurrences in 27 mg BCG was found to be superior to 13,5 BCG (RR 0.66; 95% CI 0.49-0.89, I2 = 
8.8% and p=0.006). Systemic side effects were happened in 25%, 28.5%, and 15.5% in the doses 81.27 and 
13.5 mg BCG, respectively. Low dose was superior to full dose in affecting systemic side effect (p=0,000) but 
no difference in affecting local side effect (p=0.137) in the meta-analysis of 1816 patients in 2 clinical trials. 
Conclusion: full dose BCG had superior outcome to reduce recurrences compared to low dose and very low 
dose. There were no significant differences between each dose in local side effect. However full dose regimen 
has higher systemic side effect compared to low and very low dose.
Key words: Bacillus Calmette-Gue´Rin, dose and adverse effect, non-muscle invasive bladder cancer 
(NMIBC).
INTRODUCTION
Non muscle invasive bladder cancer is 
characterized by a high risk of recurrence and 
progression to a muscle invasive disease.1 
The individual estimated risk of recurrence 
and progression can be calculated by using 
the risk score introduced by European 
organisation of Research and Treatment of 
cancer (EORTC) risk table or a simplified risk 
group classification.2,3 Intravesical instillation 
of Bacilus Calmette-Guerin ( BCG ) is the most 
effective adjuvant therapy after transurethral 
resection of intermediate or high risk superficial 
bladder tumours and recommended as the first 
line treatment for patients with carcinoma 
in situ.2,4,5 In the intermediate and high risk 
patients, the protective effect of long term 
therapy BCG are more pronounced compared 
with chemotherapy.6,7 Since the introduction 
of BCG in the mid 1970s for the treatment and 
prophylaxis of superficial bladder TCC, it has 
become the biological response modifier of 
choice for tumours at high risk of recurrence 
and progression.8 Several randomised trials and 
meta-analyses published threafter suggested that 
maintenance BCG instillations during 1-3 years 
is superior to both chemotherapy and induction 
BCG alone in reducing recurrences and even 
progression to muscle-invasive disease.3,7,9-11 
Morales et al mentioned that induction BCG 
instilation performed every 6 week and aditional 
BCG instilation reduce recurrence but optimal 
duration of maintenance instilation remains 
controversial.9,12,13 Based on several meta-
analysis, the EAU guidelines recommend at least 
1 year of maintenance.
BCG can produce either local or systemic 
adverse effects such as bacterial or chemical 
cystitis, dysuria, frequency, hematuria, granuloma 
prostatitis, epididymitis, urethral obstruction 
and contracted bladder, fever, influenza like 
symptoms include general malaise and chills, 
lung infection, liver toxicity and sepsis. The 
occurrence of adverse effects is one of the main 
reasons why urologist try to avoid the use of 
BCG, particulary in intermediate-risk patients, 
for whom chemotherapeutic agents are often 
prescribed. BCG efficacy and toxicity are dose-
dependent and the problem lies in finding a very 
low BCG dose that is effective and has low 
toxicity. A reduction in side effects might be 
achieved in several different ways, for example, 
by reducing the BCG dose, administration of 
the antituberculosis drug INH,6,14 antibiotic 
ofloxacin,15 or by reducing its dose. However, 
the optimal duration of maintenance instillation 
remains controversial.4,8,16
By the late 1980s, two groups were trying 
lower doses than normal in an attempt to 
decrease the frequency and intensity of adverse 
reactions but the lack of agreement among 
these studies induced the Spainish urological 
club for oncological treatment (CUETO: Club 
Urologico Espanol de Tratamiento Oncologico) 
to undertake a study to ascertain the therapeutic 
value and toxic effect of a three-fold lower dose 
of BCG compared with the standard dose.17,18
The aim of this study is to find effective 
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dose and evaluate dose related local as well as 
systemic side effects of BCG.
METHODS
Review Questions and Study Protocols
The proposed questions aimed to be answered 
by our study are what is the effective dose and 
what are the side effects of maintenance BCG 
in intermediate and high risk non-muscle 
invasive bladder cancer? This meta-analysis are 
conducted under guidance of Quality of reporting 
of Meta-analysis (QUOROM) statements.
Literatures Search
We searched literatures in Medline and 
Cochrane database before October 2013 using 
systematic searching strategy with keywords 
“dose and side effect”, “intermediate and high”, 
“non-muscle invasive bladder cancer”, “Bacillus 
Calmette-Guerin”. Only English language papers 
were included in this study.
Eligibility Criteria
This meta-analysis is performed based on 
published randomized controlled trials. Inclusion 
criterias were: a). publication which use single 
BCG instilation with full dose (81 mg), low 
dose (27 mg) and very low dose (13.5 mg) after 
transurethral resection, b). patient with moderate 
and high risk NMIBC, c). follow up for local 
side effects (bacterial or chemical cystitis, 
frequency, hematuria, granulomatous prostatitis, 
epididimytis, ureteral obstruction and scar tissue 
in bladder) and systemic side effects (fever more 
than 39ºC, influenza like symptoms such as chill 
and malaise, BCG induced lung infection, liver 
toxicity and sepsis induced BCG).
Exclusion criterias were: a). low risk NMIBC 
patient, b). other dose of BCG, c). invassive 
bladder cancer.
Data Extraction and Statistical Analysis
Data extracted from each trial consisted of 
sample size, mean follow up duration, BCG 
doses consisted of full dose (81 mg), low dose 
(27 mg) and very low dose (13.5 mg), regimen 
of BCG therapy, local and systemic side effect of 
each dose. Statistical analysis using Fixed effects 
model or random effects model with Mantzel 
Haenzel methods to calculate relative risk and 
95% confidence interval and compared every 
dose given. Authors assessed the heterogeneity 
by calculating the I2 statistic (low (25%-
50%), moderate (50%-75%) and high (>75%). 
All analysis performed using stata statistical 
software version 12.0 (StataCorp).
RESULTS
From 429 publications authors selected 
20 publications. There are only 6 randomized 
controlled trial (RCT) which were feasible for 
further meta-analysis (Figure 1).
Meta-analysis from 6 RCT from 2719 
patients with intermediate and high risk non 
muscle invasive bladder cancer patients, the 
recurrence rate for full dose (81 mg), low dose 
(27 mg) and very low dose (13.5 mg ) was 33.3% 
(374/1120), 27.5% (365/1323) and 30% (83/276) 
(Table 1).
429 published
publications are identified
and screened
20 publications retrieved for
more detailed evaluation
6 potentially appropriate
RCTs to be include in
meta-analysis
409 published
publications are excluded
14 publications excluded
because did not meet detailed
inclusion criteria
Figure 1. Literature searching
Meta-analysis from 4 RCT which compared 
full dose (81 mg) BCG (with the mean follow 
up 77,3 months) and low dose (27 mg) (mean 
follow up 70 months ) in 2175 patients found that 
full dose of BCG was superior over low dose in 
reducing reccurence NMIBC 33.3% and 38.5% 
respectively (RR 0.86; 95% CI 0.77-0.96, I2 = 
0% and p=0.008). (Figure 2)
The results of two RCT with 544 NMIBC 
patient with moderate and high risk patients, 
comparing effectivity of low dose BCG (268 
patient with mean follow up 58.2 months) and 
very low dose BCG (276 patient with mean follow 
up 58.5 months) to reduce reccurence rates found 
that low dose BCG was superior than very low 
dose (RR 0.66; 95%CI 0.49-0.89, I2 = 8.8% and 
p=0.006). About 20.1% patients with low dose 
Vol 46 • Number 4 • October 2014          Effective dose and adverse effects of maintenance Bacillus Calmette-Guerin
301
Table 1. Recurrence rate in clinical trial compared full dose BCG with low dose BCG as NMIBC therapy
Study Year Inclusion Criteria Therapy Regimen
Dose
P N total
Full 
dose n/N
Mean 
Follow-
up
Low 
dose n/N
Mean 
Follow-
up
Odden J 
et al1
2013 pT1G3or multipel 
pTa–T1, grade 
1–3 Bladder 
urothelial 
carcinoma
Once a week for 
6 week, After that 
every 3 week on 
3, 6, 12, and 18 
month
0.045 1355 276/677 85.2 Mo 311/678 85.2 Mo
Martinez 
JA et al8
2002 Ta, T1, dan Tis 
Bladder cancer
Once a week for 
6 week, after that 
every 2 week for 6 
times
0.58 499 29/252 69 Mo 33/247 69 Mo
Semper 
M et 
al19
2010 carcinoma insitu 
(CIS) bladder
every 3 week at 
3, 6, 12, and 18 
month
>0,05 138 34/93 76 Mo 34/93 55 Mo
Unda M 
et al20
2009 Ta-T1 GIII and or 
carcinoma insitu 
(CIS) bladder
every 3 week on 
3, 6, 12, and 18 
month
>0.05 183 35/98 79 Mo 35/98 71 Mo
Total 2175 374/1120 77.3 Mo 406/1055 70 Mo
Table 2. Recurrence rate in clinical trials compared low dose with very low dose BCG in NMIBC therapy 
Study Year Inclusion Criteria Therapy Regimen
Dose
P Total N
Low 
dose n/N
Mean 
Follow-
up
Very low 
dose n/N
Mean  
Follow-
up
Ojea A 
et al4
2007 TaG2 and T1G1-
2 bladder cancer
Once a week for 
6 weeks, continue 
every 2 week for 
12 weeks 
0.517 281 38/142 53.7 mo 50/139 61.2 mo
March N 
et al21
2002 T1G1-2 bladder 
cancer
Once every 6 
week,continue 
every 2 week for 
12 weeks 
0.58 263 16/126 62.7 mo 33/137 55.9 mo
Total 544 54/268 58.2 mo 83/276 58.5 mo
Figure 2. Forest plot reccurence rate full dose compared with low dose of BCG.
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BCG experience reccurence compare with 30% 
patient with very low dose BCG. (Figure 3)
In meta-analysis from 4 RCT with total 
2360 moderate-high risk NMIBC patient, 
incidence local side effect after full dose, low 
dose and very low dose BCG instilation were 
59.3% (537/905), 60.0% (708/1179), and 63.7% 
(176/276). Systemic side effects occured in 
25.4% (230/905), 28.5% (337/1179), and 15.5% 
(43/276) respectively.(Table 3 and 4)
In meta-analysis with 1816 patient, there 
was no significant difference in local side effect 
(p=0.137), but low dose was better to reduce 
systemic side effect (p=0.000). In meta-analysis 
with 544 patient given low dose and very low 
dose BCG also had no significant difference 
Figure 3. Forest plot reccurence rate in low dose patient compared with very low dose of BCG
Table 3. Study compared side effect full dose and low dose BCG in NMIBC therapy
Study Year Inclusion Criteria Therapy Regimen
Local side effect Systemic side effect
N 
Total
Full 
dose n/N
Low 
dose n/N
N 
Total
Full 
dose n/N
Low 
dose n/N
Brausi 
M et 
al22
2013 pT1G3 or 
multiple  pTa–
T1, grade 
1–3 urothelial 
bladder cancer
Once a week for 
6 weeks, continue 
every 3 weeks in 
3,6,12 and 18 month
1316 412/657 414/659 1316 192/657 211/659
Martinez 
JA et 
al8
2002 Ta, T1, dan Tis 
bladder cancer
Once a week for 
6 weeks, continue 
every 2 weeks for 6 
times
500 125/248 168/252 500 38/248 89/252
Total 1816 537/905 528/911 1816 230/905 300/911
Table 4. Study compared side effect low dose and very low dose BCG in NMIBC therapy
Study Year Inclusion Criteria Therapy Regimen
Local side effect Systemic side effect
N 
Total
Low dose 
n/N
Very low 
dose  
n/N
N 
Total 
Low dose 
n/N
Very low 
dose  
n/N
Ojea A 
et al4
2007 TaG2 dan 
T1G1-2 
Bladder cancer
Once every 6 
week, continue 
every 2 weeks for 
12 weeks
281 93/142 89/139 281 16/142 15/139
March 
N et al21
2002 T1G1-2 
Bladder cancer
Once a weeks for 
6 weekss, continue 
every 2 weeks for 
12 weeks
263 87/126 87/137 263 21/126 28/137
Total 544 180/268 176/276 544 37/268 43/276
Vol 46 • Number 4 • October 2014          Effective dose and adverse effects of maintenance Bacillus Calmette-Guerin
303
(p=0.400) and (p=0.600) (Figure 4 and 5).
DISCUSSION
Over 35 years ago, Morales et al published 
the first study on the use of intravesical BCG 
immunotherapy for NMIBC.22 Efficacy of 
BCG instillation does not seem to be increased 
significantly when combined with intradermal 
BCG vaccination simultaneously.21 Since 
then, several meta-analysis have shown that 
adjuvant intravesical treatment reduces NMIBC 
recurrency. The choice between adjuvant 
intravesical tratments, namely chemotherapy or 
BCG immunotherapy, depends on the risk that 
needs to be reduced : recurrence or progressive. 
Intravesical instillation of BCG reduces 
the risk of recurrence and delays the time to 
reccurence compared with transurethral alone 
or other drugs given intravesically. However 
the mechanism is not completely understood. 
The Japanese groups suggest that cytokines play 
an important role in the effector mechanism of 
BCG, especially interleukin-2 (IL-2) that can 
be used to monitor the reaction of a patient to 
BCG.23 This can be used to classify responders 
and non responders to BCG and tailored BCG 
schedule and doses.24 Based on meta-analysis, 
maintenance BCG schedule was found to be 
essential in preventing progression.25 Despite this 
advantages, BCG is not free from complications 
such as bacterial or chemical cystitis, dysuria, 
frequency, hematuria, granuloma prostatitis, 
epididymitis, urethral obstruction and contracted 
bladder, fever, influenza like symptoms include 
general malaise and chills, lung infection, liver 
toxicity and sepsis.
A clinical trial by Ojea et al. and March et 
al., on 544 moderate-high risk NMIBC patients 
found that low dose BCG was more effective and 
significantly reduce recurrence compared to very 
low dose. Oden et al., Martinez et al., Semper 
et al., and Unda  et al., who compare full dose 
with low dose in 2175 patient found that full dose 
seems better in reducing the reccurence of tumor.
Figure 4. Forest plot local side effect of full dose, low dose and very low dose BCG
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The mechanisms by which BCG leads to 
the development of infectious complications 
is not fully understood. One explanation is its 
action as an immunotherapeutic agent on helper 
T cell cytokine profile known as the “Th1 
response”.26 Considerable debate exists about 
whether infectious complications due to BCG 
represent a hypersensitivity reaction or ongoing 
active infection. The hypersensitivity hypothesis 
gained early attention based upon the presence 
of granulomas and the absence of recoverable 
organisms. In a number of case reports, acid-
fast bacilli have not been demonstrated and 
organisms have not grown despite a high clinical 
suspicion of BCG infection.27,28 A response 
to glucocorticoids, administered along with 
antituberculous drugs, has also supported the 
notion of a hypersensitivity response.
The fastidious growth nature of BCG in 
culture and a doubling time of 24 to 48 hours 
contribute to the difficulty in its isolation. It should 
be emphasized that >95% of patients tolerated 
BCG without significant morbidity. Most of 
symptoms associated with BCG immunotherapy 
are a result of immune stimulation that is 
required to effectively eradicate cancer cells. 
These symptoms include urinary frequency and 
burning, mild malaise and low grade fever.29
Local side effect includes bacterial or 
chemical cystitis, dysuria, frequency, haematuria, 
granulomatous prostatitis, epididymitis, urethral 
obstruction and contracted bladder. The most 
common local side effect was drug induced 
cystitis, manifested as iritative voiding with 
negative urine culture and hematuria that 
resolves in 48 hours without the need to stop 
BCG instilation.30-32 Systemic side effects 
include fever (>39oC), influenza like symptoms, 
including general malaise and chills, BCG 
induced lung infection, liver toxicity, and sepsis. 
Figure 5. Forest plot systemic side effect of full dose, low dose and very low dose BCG
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Even, rare severe systemic reaction of BCG can 
be found due to active infection with immune 
response, such as systemic granulomatous 
disease with high fever that can progressed into 
multi organ failure. Onset of the symptoms can 
be months until years after last instilation. This 
phenomenon may be due to the prescence of 
BCG for long time in body. Skin rash, atralgia 
and arthritis were classified as possible allergic 
reactions. Fever, which occurred predominantly 
in BCG-sensitised patients, was the only factor in 
a multivariate analysis significantly related to a 
decreased recurrence rate and increased toxicity. 
Drug related life threatening side effect such as 
septic BCG could be occurred due to systemic 
BCG absorption.30
Maintenance BCG has been suggested 
by many authors as the treatment of choice 
for patients with high risk superficial bladder 
cancer or carcinoma insitu.25,28 This is reflected 
in various guidelines on non muscle invassive 
bladder cancer that include BCG as first line 
adjuvant therapy after transurethral resection 
in high risk patient.2,5 The widely accepted 
maintenance schedule is based on southwest 
oncology group regimen, starting with series of 
six weekly induction followed by three weekly 
instilation at 3 months and then every 6 months 
for 3 year.9 European Association of Urology 
Guidelines recommend at least 1 year of BCG 
maintenance therapy.2 However, the side effects 
make urologists reluctant to administer BCG to 
their patient when the disease is not high risk.
Thus, it is important to decrease BCG toxicity 
while maintaining its efficacy. There are some 
ways to overcome the BCG side effects such 
as administration of isoniazid 300 mg daily 
or dose reduction. Patient with evidence of 
BCG infection such as epididimytis, hepatitis 
or symptomatic prostatitis are treated with 
isoniazid plus rifampin 600 mg daily. In EORTC 
trial in which intravesical epirubicin, BCG and 
BCG plus isoniazid were compared in 957 
patients. Isoniazid does not seem to reduce 
the side effects of BCG. The most dangerous 
complication of BCG is systemic septic and/
or hypersensitivity reaction, characterized by 
chills, fever, hypotension, and progressive multi 
organ failure but the incidence of this event is 
very low 0.4%.29
In 2012, Brausi21 compared side effects of 
low dose (27 mg) with full dose (81 mg) of 
maintenance BCG and concluded no significant 
difference in toxicity was detected according to 
dose (one-third dose vs full dose) or duration 
of treatment. A randomized prospective trial 
comparing a standard full dose (81 mg) of 
intravesical BCG with a reduced dose (27 mg) in 
superficial bladder cancer showed the proportion 
of patient with no toxicity, either local or 
systemic, was significantly higher in the reduced 
dose than in stnadard dose.8 The difference in 
severe systemic toxicity were not significant, 
indeed 4.4% of patient in the reduce dose group 
and 3.6% in the standard dose. Neither life –
threatening episodes nor sepsis were reported for 
either group. There is a report of granulomatous 
epididimytis and simultanoeus polyneuropathy 
in reduced dose patient, but whether it was 
caused by BCG is unclear.
A randomized prospective trial comparing 
adjuvant therapy for intermediate risk superficial 
bladder cancer between one-third dose, full dose 
BCG and mitomycin C concludes the disease 
free interval was significantly longer after 
treatment with BCG 27 mg and the number of 
recurrence was lower in BCG 27 mg than in 30 
mg mitomycin C group. This study suggests 
that the minimum effective dose of BCG is one 
third of the standard dose. One sixth of standard 
dose is not indicated as adjuvant treatment for 
superficial bladder cancer of intermediate risk 
because it has the same efficacy as mitomycin C 
30 mg but is more toxic. In fact, the toxicity level 
of one sixth of the standard dose is similar to that 
observed with one third of the standard dose.4
March21 in his study compared 30 mg MMC 
with 27 mg and 13.5 mg BCG as adjuvant 
therapy in medium and low risk superficial 
bladder cancer. The recurrent rate was lower in 
27 mg BCG group but the time to recurrence also 
higher in this group. No significant difference 
between other groups, and there were no 
significant difference in adverse effect between 
the two BCG treatment groups.
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CONCLUSION 
Full dose (81 mg) of BCG showed slightly 
superior effect in reducing recurrences compared 
to low and very low dose in moderate–high risk 
non muscle invasive bladder cancer following 
transurethral resection. Low dose BCG had 
less systemic side effect compared to full 
dose, however it had no difference in all doses 
regimen for local side effects. BCG instilation 
in moderate-high risk NMIBC patient should 
be considered as primary therapy in Indonesia.
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